LONDON - (AP) GlaxoSmithKline PLC says U.S. patent litigation over the Omega-3 Lovaza drug has been settled, allowing generic drug company Apotex to eventually bring a competitor to market. Glaxo said Wednesday that Norway's Pronova BioPharma, which supplies the heart medicine to Glaxo, has reached a deal that gives Apotex the right. . . . Full version available to lexis.com subscribers.